Bo
Boehringer
Ingelheim DEFounded 188553,000 employees
Private CappharmaPrivateRespiratoryOncologyMetabolic
Platform: Spesolimab IL36
Market Cap
N/A
All Drugs
2
Clinical Trials
4
Failed / Terminated
0
FDA Approved
1
Drug Pipeline (2 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| Kemasacituzumab | BOE-6326 | Approved | 3 | HER2 | CTCL | ||
| BOE-3317 | BOE-3317 | Phase 1/2 | 1 | EGFR | UCPNH |
Financial Documents
This is a private company — SEC filings are not available.
Catalyst Events (3)